FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4200564224> ?p ?o ?g. }

• W4200564224 endingPage "54" @default.
• W4200564224 startingPage "44" @default.
• W4200564224 abstract "Tumour burden (TB) is implicated in resistance to programmed cell death-1/PD-L1 inhibitor (immune checkpoint inhibitor [ICI]) therapy. However, whether TB contributes to such resistance in non-small-cell lung cancer (NSCLC) has remained unknown.A total of 260 treatment-naïve patients with advanced NSCLC who started ICI monotherapy (ICI cohort), platinum-doublet therapy (Chemo cohort) or ICI and platinum-doublet therapy (ICI+Chemo cohort) as first-line treatment were consecutively included. TB was estimated on the basis of the sum of the diameters of measurable target lesions as per Response Evaluation Criteria in Solid Tumours. Progression-free survival (PFS) in the ICI cohort was evaluated as per TB as a preplanned primary objective, with the analysis based on propensity score-weighted survival curves and estimation of restricted mean survival time (RMST). The Chemo cohort served as a control to determine whether TB is predictive of ICI treatment outcomes. The ICI+Chemo cohort was exploratory. The relation of TB to tumour immune status was assessed by immune-related gene expression profiling (irGEP) of pretreatment tumour tissue.In the ICI cohort, patients with a low TB showed a significantly longer PFS than did those with a high TB (median, 17.9 vs 4.3 months; weighted hazard ratio, 0.32 [95% confidence interval, 0.19-0.53]). No such difference was apparent in the other cohorts. A significant difference in overall survival was also observed only in the ICI cohort. RMST-based analysis confirmed these results. The irGEP analysis implicated M2-type macrophages, angiogenesis and transforming growth factor-β as well as protumourigenic signalling pathways in ICI resistance conferred by a high TB.A high TB was associated with a poor outcome of ICI therapy for advanced NSCLC as a result of immunosuppressive phenotypes. Development of combination or novel treatment strategies for such disease is thus warranted." @default.
• W4200564224 created "2021-12-31" @default.
• W4200564224 creator A5004282323 @default.
• W4200564224 creator A5007422276 @default.
• W4200564224 creator A5015271832 @default.
• W4200564224 creator A5024261346 @default.
• W4200564224 creator A5029728563 @default.
• W4200564224 creator A5038101792 @default.
• W4200564224 creator A5050706990 @default.
• W4200564224 creator A5051748580 @default.
• W4200564224 creator A5052161758 @default.
• W4200564224 creator A5054647319 @default.
• W4200564224 creator A5060266548 @default.
• W4200564224 creator A5065856332 @default.
• W4200564224 creator A5066972885 @default.
• W4200564224 creator A5076568893 @default.
• W4200564224 creator A5077151296 @default.
• W4200564224 creator A5087401551 @default.
• W4200564224 creator A5089345348 @default.
• W4200564224 date "2022-01-01" @default.
• W4200564224 modified "2023-10-02" @default.
• W4200564224 title "Association of tumour burden with the efficacy of programmed cell death-1/programmed cell death ligand-1 inhibitors for treatment-naïve advanced non-small-cell lung cancer" @default.
• W4200564224 cites W1997944395 @default.
• W4200564224 cites W2011284201 @default.
• W4200564224 cites W2195297470 @default.
• W4200564224 cites W2293531514 @default.
• W4200564224 cites W2425731878 @default.
• W4200564224 cites W2527905628 @default.
• W4200564224 cites W2533508881 @default.
• W4200564224 cites W2582686270 @default.
• W4200564224 cites W2605630275 @default.
• W4200564224 cites W2635951006 @default.
• W4200564224 cites W2648296251 @default.
• W4200564224 cites W2760699482 @default.
• W4200564224 cites W2781947653 @default.
• W4200564224 cites W2783370150 @default.
• W4200564224 cites W2784283849 @default.
• W4200564224 cites W2785091318 @default.
• W4200564224 cites W2794419219 @default.
• W4200564224 cites W2801510798 @default.
• W4200564224 cites W2888518905 @default.
• W4200564224 cites W2914311090 @default.
• W4200564224 cites W2920270836 @default.
• W4200564224 cites W2921622709 @default.
• W4200564224 cites W2925446385 @default.
• W4200564224 cites W2937823726 @default.
• W4200564224 cites W2945629214 @default.
• W4200564224 cites W2955008365 @default.
• W4200564224 cites W2961686530 @default.
• W4200564224 cites W2972923962 @default.
• W4200564224 cites W2982690310 @default.
• W4200564224 cites W2989142611 @default.
• W4200564224 cites W2998795792 @default.
• W4200564224 cites W3008753028 @default.
• W4200564224 cites W3012080769 @default.
• W4200564224 cites W3091399767 @default.
• W4200564224 cites W3098781229 @default.
• W4200564224 doi "https://doi.org/10.1016/j.ejca.2021.11.011" @default.
• W4200564224 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/34922263" @default.
• W4200564224 hasPublicationYear "2022" @default.
• W4200564224 type Work @default.
• W4200564224 citedByCount "6" @default.
• W4200564224 countsByYear W42005642242022 @default.
• W4200564224 countsByYear W42005642242023 @default.
• W4200564224 crossrefType "journal-article" @default.
• W4200564224 hasAuthorship W4200564224A5004282323 @default.
• W4200564224 hasAuthorship W4200564224A5007422276 @default.
• W4200564224 hasAuthorship W4200564224A5015271832 @default.
• W4200564224 hasAuthorship W4200564224A5024261346 @default.
• W4200564224 hasAuthorship W4200564224A5029728563 @default.
• W4200564224 hasAuthorship W4200564224A5038101792 @default.
• W4200564224 hasAuthorship W4200564224A5050706990 @default.
• W4200564224 hasAuthorship W4200564224A5051748580 @default.
• W4200564224 hasAuthorship W4200564224A5052161758 @default.
• W4200564224 hasAuthorship W4200564224A5054647319 @default.
• W4200564224 hasAuthorship W4200564224A5060266548 @default.
• W4200564224 hasAuthorship W4200564224A5065856332 @default.
• W4200564224 hasAuthorship W4200564224A5066972885 @default.
• W4200564224 hasAuthorship W4200564224A5076568893 @default.
• W4200564224 hasAuthorship W4200564224A5077151296 @default.
• W4200564224 hasAuthorship W4200564224A5087401551 @default.
• W4200564224 hasAuthorship W4200564224A5089345348 @default.
• W4200564224 hasBestOaLocation W42005642241 @default.
• W4200564224 hasConcept C10515644 @default.
• W4200564224 hasConcept C121608353 @default.
• W4200564224 hasConcept C126322002 @default.
• W4200564224 hasConcept C143998085 @default.
• W4200564224 hasConcept C201903717 @default.
• W4200564224 hasConcept C207103383 @default.
• W4200564224 hasConcept C2776256026 @default.
• W4200564224 hasConcept C2777701055 @default.
• W4200564224 hasConcept C2781053074 @default.
• W4200564224 hasConcept C44249647 @default.
• W4200564224 hasConcept C50382708 @default.
• W4200564224 hasConcept C71924100 @default.
• W4200564224 hasConcept C72563966 @default.
• W4200564224 hasConceptScore W4200564224C10515644 @default.
• W4200564224 hasConceptScore W4200564224C121608353 @default.

• next